[{"NetIncomeLoss_1_Q2_USD":-27619000.0,"InterestPaidNet_2_Q2_USD":23000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":-416000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q2_USD":101027000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":381000.0,"AssetsCurrent_0_Q2_USD":276658000.0,"OperatingLeaseExpense_2_Q2_USD":194000.0,"OperatingLeaseExpense_1_Q2_USD":85000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_2_Q2_shares":4041000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q2_USD":497000.0,"DueToRelatedPartiesCurrent_0_Q2_USD":106000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":372000.0,"CommonStockSharesIssued_0_Q2_shares":27969000.0,"Assets_0_Q2_USD":281107000.0,"ShareBasedCompensation_2_Q2_USD":12334000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":1377000.0,"PreferredStockParOrStatedValuePerShare_0_Q2_USD":0.001,"ProceedsFromIssuanceOfCommonStock_2_Q2_USD":101027000.0,"ProceedsFromIssuanceOfCommonStock_0_Q2_USD":96971000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_0_Q2_USD":64000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":9557000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":24962000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":28250000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":13509000.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":1749000.0,"CommonStockValue_0_Q2_USD":28000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2_Q2_USD":559000.0,"DepreciationDepletionAndAmortization_2_Q2_USD":144000.0,"DepreciationDepletionAndAmortization_1_Q2_USD":80000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":102376000.0,"StockIssuedDuringPeriodSharesNewIssues_0_Q2_shares":3155000.0,"LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0_Q2_USD":213000.0,"PaymentsOfStockIssuanceCosts_1_Q2_USD":3542000.0,"OtherAssetsNoncurrent_0_Q2_USD":1630000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":273057000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":1255000.0,"Liabilities_0_Q2_USD":13696000.0,"OperatingLeaseLiability_0_Q2_USD":1536000.0,"PreferredStockSharesOutstanding_0_Q2_shares":0.0,"GeneralAndAdministrativeExpense_2_Q2_USD":25742000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":14104000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":24744000.0,"PaymentsOfStockIssuanceCosts_0_Q2_USD":3042000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":178000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":391000.0,"CommonStockSharesAuthorized_0_Q2_shares":100000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":59938000.0,"CommonStockSharesOutstanding_0_Q2_shares":27969000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q2_USD":506000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":6769000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-42022000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":363000.0,"LiabilitiesCurrent_0_Q2_USD":12441000.0,"AccountsPayableCurrent_0_Q2_USD":2497000.0,"InterestExpense_2_Q2_USD":23000.0,"InterestExpense_1_Q2_USD":16000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q2_USD":273057000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":3601000.0,"ProceedsFromStockOptionsExercised_2_Q2_USD":1349000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":62000.0,"AdditionalPaidInCapital_0_Q2_USD":460235000.0,"NumberOfOperatingSegments_2_Q2_segment":1.0,"PreferredStockSharesIssued_0_Q2_shares":0.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":1442000.0,"NetIncomeLoss_2_Q2_USD":-53995000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-192852000.0,"TaxesPayableCurrent_0_Q2_USD":254000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":416000.0,"StockholdersEquity_0_Q2_USD":267411000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_2_Q2_USD":null,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q2_USD":null,"OperatingIncomeLoss_2_Q2_USD":-53992000.0,"OperatingIncomeLoss_1_Q2_USD":-27613000.0,"InvestmentIncomeInterest_2_Q2_USD":20000.0,"InvestmentIncomeInterest_1_Q2_USD":10000.0,"PreferredStockValue_0_Q2_USD":null,"LiabilitiesAndStockholdersEquity_0_Q2_USD":281107000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":2359000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":1064000.0,"PreferredStockSharesAuthorized_0_Q2_shares":10000000.0,"AllocatedShareBasedCompensationExpense_1_Q2_USD":6769000.0,"PropertyPlantAndEquipmentGross_0_Q2_USD":1948000.0,"SharePrice_0_Q2_USD":31.7,"OperatingLeaseLiabilityCurrent_0_Q2_USD":281000.0,"OperatingExpenses_2_Q2_USD":53992000.0,"OperatingExpenses_1_Q2_USD":27613000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-2.18,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-1.11,"OtherLiabilitiesCurrent_0_Q2_USD":281000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":12334000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":3294000.0,"Ticker":"BTAI","CIK":"1720893","name":"BIOXCEL THERAPEUTICS, INC.","OfficialName":"BioXcel Therapeutics Inc. Common Stock","form":"10-Q","period":"20210630","fy":"2021.0","fp":"Q2","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"417746551.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210810"}]